Telix Pharmaceuticals shares (ASX:TLX) jumped to lead the ASX 200 after announcing a major global collaboration with US biotech giant Regeneron Pharmaceuticals to develop next-generation cancer treatments, marking a pivotal validation of its radiopharmaceutical platform.
The Telix share price climbed 5.46% to A$15.44 heading into the final half hour of trading, placing the company at the top of the benchmark index, and extended into the close, up 7.72% at A$15.77. The rally extends a remarkable recovery for the stock, which has now surged approximately 80% from its February lows after enduring a brutal 65% drawdown through 2025. The rebound reflects a dramatic shift in market sentiment from heavy short interest and regulatory concerns toward renewed optimism about the company’s commercial trajectory and pipeline potential.
Details of the Regeneron Agreement
The collaboration centres on a 50/50 global cost and profit-sharing structure for developing radiopharmaceutical therapies targeting solid tumours. Regeneron will pay Telix US$40 million upfront for four initial therapeutic programs, with options to expand the partnership to include up to four additional programs.
The financial terms carry substantial long-term upside for Telix. The company stands to receive up to US$2.1 billion in combined development and commercial milestone payments, plus low double-digit royalties on any program where it elects to step back from co-funding and instead take a passive economic interest. This flexible structure allows Telix to balance risk and reward across its portfolio, choosing between full participation in profits or de-risked milestone and royalty streams on a program-by-program basis.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
Beyond therapeutics, the partnership also encompasses joint development of radio-diagnostic imaging agents. Telix will lead commercialisation of these diagnostic products while sharing profits with Regeneron, leveraging its established infrastructure in nuclear medicine imaging.
The scientific rationale combines Telix’s expertise in radiopharmaceutical chemistry, manufacturing, and regulatory pathways with Regeneron’s proprietary antibody discovery platforms and deep oncology development capabilities. The collaboration targets cancers with significant unmet medical needs, including lung cancer and other solid tumours where current treatment options remain limited.
The Regeneron deal arrives as Telix demonstrates robust commercial execution. The company reported fiscal 2025 revenue of approximately US$804 million, meeting guidance and reflecting strong uptake of its flagship prostate cancer imaging agent Illuccix, alongside contributions from newer products including kidney cancer imaging agent TLX250-Px (marketed as Gozellix in some territories).
Management has guided to group revenue of US$950 million to US$970 million for 2026, implying continued top-line expansion approaching the US$1 billion milestone. However, the company is simultaneously investing heavily in research and development, with 2026 R&D spend expected to reach approximately US$200 million to US$240 million as it advances multiple late-stage clinical programs and expands manufacturing infrastructure.
Upcoming Regulatory Catalysts
Beyond the Regeneron partnership, Telix faces a critical regulatory milestone in September 2026 when the US Food and Drug Administration is scheduled to complete its review of TLX101-Px (Pixclara), a PET imaging agent for recurrent and progressive glioma. The company resubmitted its New Drug Application in March 2026 following earlier discussions with the agency regarding manufacturing comparability.
Approval of Pixclara would extend Telix’s commercial footprint into neuro-oncology and validate its platform in brain cancer imaging, potentially de-risking related therapeutic candidates targeting the same biology. The FDA decision represents the next major binary catalyst for the stock after today’s partnership announcement.
International expansion efforts are also progressing. China’s National Medical Products Administration accepted Telix’s New Drug Application for Illuccix in January 2026, opening a pathway to one of the world’s largest healthcare markets. Additionally, TLX250-Px received inclusion in updated international imaging guidelines from leading nuclear medicine societies, supporting standard-of-care adoption for kidney cancer diagnosis.
Manufacturing and Infrastructure Build-Out
Telix has committed substantial capital to vertical integration across the radiopharmaceutical supply chain. The company is expanding radioisotope production capacity in Belgium and the Americas, investing in cyclotron infrastructure, and securing access to novel isotopes including lead-212 for future alpha-radiotherapy programs. This build-out aims to reduce supply-chain risk and create competitive barriers, though it contributes to elevated capital expenditure and near-term cash consumption.
The company has also entered strategic collaborations beyond Regeneron. A clinical partnership with Varian, a Siemens Healthineers company, will explore combining Telix’s targeted radiopharmaceuticals with external beam radiation therapy to optimise treatment protocols. Separately, Telix is participating in the PROMISE-PET registry with University Hospital Essen to develop artificial intelligence-based prognostic models using PSMA PET scan data, positioning the company at the intersection of radiopharmaceuticals and AI-driven precision oncology.
Outlook
The Regeneron collaboration fundamentally reframes Telix’s investment narrative. Rather than a niche imaging specialist, the company now positions as a preferred partner for big pharma seeking radiopharmaceutical capabilities, with economics that could rival large-cap biotech partnerships if programs advance successfully.
The company’s ability to balance growth investment with margin expansion will also remain a key focus for markets. While revenue approaching US$1 billion supports a substantial valuation, profitability and free cash flow generation matter increasingly as biotech investors shift toward quality and self-funding models in a higher-rate environment.
Telix shares are clearly back in favour in recent weeks, following a more than challenging 2025, although those that were put off by valuation are unlikely to be swayed by today’s deal.
Bull Case:
- US$40 million upfront validates platform; US$2.1 billion milestone potential expands TAM significantly
- Commercial revenue approaching US$1 billion demonstrates rare cash-generating radiopharma at scale
- Vertical integration in isotope production and manufacturing creates durable competitive moat
- Multiple pipeline shots across prostate, kidney, brain, and solid tumours diversify risk
- Tier-one partnerships with Regeneron and Varian position Telix as core platform player
Bear Case:
- 50/50 cost-sharing maintains elevated R&D burn; near-term profitability and cash flow uncertain
- September Pixclara FDA decision represents major binary risk; CRL would trigger sharp downside
- Most Regeneron milestone value contingent on clinical success years away; early-stage risk high
- Intensifying big pharma competition in radiopharmaceuticals threatens market share and pricing power
- Complex multi-program execution across manufacturing, clinical trials, and regulatory pathways increases operational risk
